05 January 2023
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and preliminary U.S. ZTALMY® net product revenue for the fourth quarter and year ended December 31, 2022.
19 December 2022
San Francisco, December 19, 2022 – Cothera Bioscience today announced that it has dosed the first patient with PC-002, a first-in-class deubiquitinase (DUB) inhibitor, in a global multi-center phase 2 clinical trial for the treatment of high-grade B-cell lymphoma with Myc rearrangement (NCT05263583). This is a single-arm, single-agent proof-of-concept trial designed to evaluate PC-002 in patients who are either resistant or refractory to prior treatments.
17 November 2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a collaboration and supply agreement with Tenacia Biotechnology (Shanghai) Co., Ltd., a China-based biotechnology company focused on the development of innovative treatments for central nervous system (CNS) disorders.
Marinus Pharmaceuticals Appoints CEO Scott Braunstein, M.D., as Chairman of the Board
17 November 2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that the Board of Directors has appointed Chief Executive Officer (CEO) and Board Director, Scott Braunstein, M.D., as Chairman of the Board. Dr. Braunstein succeeds Nicole Vitullo, who has retired from the Board of Directors following a 17-year tenure, including the past three years as Chairwoman.
11 November 2022
binx health, a healthcare technology and diagnostics company focused on making routine testing convenient, today announced a strategic agreement with Afaxys Group Services LLC to expand access to sexual health and wellness testing nationally through their Group Purchasing Organization (GPO). Under the agreement, binx will offer its FDA-cleared, CLIA-waived point-of-care test for chlamydia (CT) and gonorrhea (NG) and its at-home digital health platform to thousands of clinics across the United States, under a preferred pricing model with joint marketing outreach among Afaxys and binx.
Marinus Pharmaceuticals Announces Pricing of $60 Million Public Offering
08 November 2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the pricing of its underwritten public offering of 10,526,316 shares of its common stock at a public offering price of $4.75 per share, and, to certain investors in lieu of common stock, pre-funded warrants to purchase 2,105,264 shares of common stock at a price of $4.749 per pre-funded warrant, for gross proceeds of approximately $60 million, before deducting underwriting discounts and commissions and offering expenses payable by Marinus.
Marinus Pharmaceuticals Announces Proposed Public Offering
08 November 2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has commenced an underwritten public offering of its securities. All of the securities to be sold in the offering are being offered by Marinus. In addition, Marinus expects to grant the underwriters a 30-day option to purchase up to an additional 15 percent of the number of securities offered in the public offering at the public offering price, less underwriting discounts and commissions.
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results
08 November 2022
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2022.
01 November 2022
Epic Sciences, Inc. (“Epic” or “Epic Sciences”), a privately held diagnostics company, announces the appointment of William J. Kullback as Chief Financial Officer (CFO), while previous CFO, Joel S. Smith, will continue in his other executive roles as General Counsel, Chief Compliance Officer, and Executive Vice President of Corporate Development.
01 November 2022
binx health, a healthcare technology and women’s health company focused on making routine testing broadly accessible and convenient, announced today the launch of its instrument placement program for CLIA-waived facilities. This program eliminates all upfront instrument costs, enabling access to rapid testing and helping pave the way to better health outcomes. CT and NG are two of the most tested for sexually transmitted infections (STIs). With millions of CT/NG tests processed at central laboratories annually, and 230,000 CLIA-waived sites across the United States, the binx io can be a catalyst for transforming how and where STI’s are diagnosed and treated.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Putin has stated that Russia will support Africa in the struggle against epidemics
19 April 2024
The Russian government has expanded the list of vital and essential drugs
19 April 2024
Achieving FAIR bacterial identification
18 April 2024
Unique testing regimen could prevent nuclease contamination
18 April 2024